Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Cho Ming Loi"'
Autor:
Patrick W. Vincent, Haile Tecle, Helen T. Lee, Jianxin Yang, Deborah A. Baker, Daniel J. Lettiere, Alex J. Bridges, Jessica E. Reed, R. Thomas Winters, Karen E. Sexton, Kevin M. Schlosser, Stephen A. Fakhoury, Cho-Ming Loi, Tong Zhu, David W. Fry, James M. Nelson, Danielle M. Amato, Teresa A. Ellis, Patricia J. Harvey, Amy M. Delaney, Erin Trachet, Paul A. Ellis, Irene W. Althaus, Kenneth E. Hook, Andrea J. Gonzales
Supplementary Fig. S3 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a40c0cb9dee2febea61bbf447bdf801
https://doi.org/10.1158/1535-7163.22483889
https://doi.org/10.1158/1535-7163.22483889
Autor:
Patrick W. Vincent, Haile Tecle, Helen T. Lee, Jianxin Yang, Deborah A. Baker, Daniel J. Lettiere, Alex J. Bridges, Jessica E. Reed, R. Thomas Winters, Karen E. Sexton, Kevin M. Schlosser, Stephen A. Fakhoury, Cho-Ming Loi, Tong Zhu, David W. Fry, James M. Nelson, Danielle M. Amato, Teresa A. Ellis, Patricia J. Harvey, Amy M. Delaney, Erin Trachet, Paul A. Ellis, Irene W. Althaus, Kenneth E. Hook, Andrea J. Gonzales
Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types. Abnormalities in members of this receptor family have been shown to play a role in o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1992a9e6a0fff9d2a73c053cb1cf91a6
https://doi.org/10.1158/1535-7163.c.6531266.v1
https://doi.org/10.1158/1535-7163.c.6531266.v1
Publikováno v:
Drug Metabolism and Disposition. 46:1200-1211
Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Ph+ chronic myelogenous leukemia at a clinically recommended dose of 500 mg once daily. Clinical results indicated that increases in bosut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69184dc2fba70e7e3900f7baffe1038b
https://doi.org/10.1124/dmd.118.080424
https://doi.org/10.1124/dmd.118.080424
Publikováno v:
Drug Metabolism and Disposition. 45:390-398
Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib is predominantly metabolized by CYP3A4 as the primary clearance m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce4d6c9be3837937ac6e347b3626298f
https://doi.org/10.1124/dmd.116.074450
https://doi.org/10.1124/dmd.116.074450
Publikováno v:
The Journal of Clinical Pharmacology. 57:173-184
Palbociclib is an orally available CDK4/6 inhibitor. In humans, palbociclib undergoes metabolism mediated primarily by CYP3A and SULT2A1, and it is also a weak time-dependent CYP3A inhibitor. The objectives of the current study are to (1) develop a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e844b14fda3142d4ab53e41bba29e4a
https://doi.org/10.1002/jcph.792
https://doi.org/10.1002/jcph.792
Publikováno v:
Drug Metabolism and Disposition. 41:933-951
Characterization of the circulating metabolites for a new chemical entity in humans is essential for safety assessment, an understanding of their contributions to pharmacologic activities, and their potential involvement in drug-drug interactions. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28a9ed83483ceb0811132ca01e0d3727
https://doi.org/10.1124/dmd.112.050278
https://doi.org/10.1124/dmd.112.050278
Autor:
Cho-Ming Loi, James Kalabus, Guangqing Xiao, Wen Lin, Yingying Guo, William Brian, Ruben de Kanter, Larry M. Tremaine, Raymond Evers, Million Arefayene
Publikováno v:
Pharmacogenomics. 17(6)
Genetic variants of drug metabolism enzymes and transporters can result in high pharmacokinetic and pharmacodynamic variability, unwanted characteristics of efficacious and safe drugs. Ideally, the contributions of these enzymes and transporters to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00eb897c1c7de7832d636ea37eef5f05
https://pubmed.ncbi.nlm.nih.gov/27045656
https://pubmed.ncbi.nlm.nih.gov/27045656
Autor:
Scott Fountain, Carol Cronenberger, Cho-Ming Loi, Eugenia Kraynov, Michel Awwad, Martin E. Dowty, Owen Fields, Susan Hurst, Steven W. Martin, Bing Kuang, Odette A. Fahmi, Diane Wang
Publikováno v:
Drug Metabolism and Disposition. 39:1779-1783
Increasing use of therapeutic proteins (TPs) in polypharmacy settings calls for more in-depth understanding of the biological interactions that can lead to increased toxicity or loss of pharmacological effect. Factors such as patient population, medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be9070e963bae4805e883fa9f2a4e1e0
https://doi.org/10.1124/dmd.111.040808
https://doi.org/10.1124/dmd.111.040808
Autor:
Angus N. R. Nedderman, Dennis A. Smith, Cho-Ming Loi, Lance Goulet, Hai-Zhi Bu, Susan Hurst, R. Scott Obach, Evan Smith, Ping Kang, Deepak Dalvie, Chandra Prakash
Publikováno v:
Chemical Research in Toxicology. 22:357-368
An early understanding of key metabolites of drugs is crucial in drug discovery and development. As a result, several in vitro models typically derived from liver are frequently used to study drug metabolism. It is presumed that these in vitro system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad5e4010a43efcdc6c0c52cf66db51e
https://doi.org/10.1021/tx8004357
https://doi.org/10.1021/tx8004357
Autor:
Xinmin Gan, Laurence Philippe, Brian Sanchez, Karen M. Yates, Ziqiang Wang, Arun K. Agrawal, Pil H. Lee, Cho Ming Loi, Zhen Lou, Haile Tecle, Jo Ann Dumin, Sheila Guppy, Frank Riley, Joan K. Brieland, Christopher James Deur, Sally Przybranowski, Brian Samas, Amy Mae Bunker, Mark Morris, Michael William Wilson, John Richard Booth, Joseph A. Cornicelli, Susan E. Bove, Cleo J. C. Connolly, Gregg Kamilar, Kenneth S. Kilgore, Barry C. Finzel, Heidi Baum, Kathryn A. Welch
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:4599-4603
It has been hypothesized that peripherally restricted NMDA receptor antagonists may be effective analgesics for osteoarthritis pain. A class of novel quinoxalinedione atropisomers, first discovered for an NMDA receptor antagonist program for the trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dcf8a8aa89569f777c79f4224db99ed
https://doi.org/10.1016/j.bmcl.2007.05.083
https://doi.org/10.1016/j.bmcl.2007.05.083